Aileron Therapeutics Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy

Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach

Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference

Aileron Therapeutics Reports First Quarter 2019 Financial Results

Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8

Aileron Therapeutics Completes $26M Private Placement

Aileron Therapeutics Announces Pricing of $26M Private Placement

Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer

Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting